Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Revvity wird ein jährliches Gewinn- und Umsatzwachstum von 19.8% bzw. 6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 19% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 7.8% betragen.

Wichtige Informationen

19.8%

Wachstumsrate der Gewinne

19.0%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum	18.3%
Wachstumsrate der Einnahmen	6.0%
Zukünftige Eigenkapitalrendite	7.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	19 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Jan 04

Revvity: More Than A Name Change Is Needed For PerkinElmer

Dec 29

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Dec 20

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Oct 07

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Oct 04

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Sep 22

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Aug 17

Revvity: New Name - But New Investment Outlook? Reiterate Buy

Jul 18

Revvity (NYSE:RVTY) Seems To Use Debt Quite Sensibly

Jul 03

What Does Revvity, Inc.'s (NYSE:RVTY) Share Price Indicate?

Jun 17

Calculating The Fair Value Of Revvity, Inc. (NYSE:PKI)

May 16

We Think PerkinElmer (NYSE:PKI) Can Stay On Top Of Its Debt

Mar 28

When Should You Buy PerkinElmer, Inc. (NYSE:PKI)?

Mar 13

Gewinn- und Umsatzwachstumsprognosen

NYSE:RVTY - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,128	398	740	830	11
12/31/2025	2,913	330	675	759	15
12/31/2024	2,757	269	562	651	13
9/29/2024	2,722	258	564	651	N/A
6/30/2024	2,708	197	383	469	N/A
3/31/2024	2,726	183	97	175	N/A
12/31/2023	2,751	180	10	91	N/A
10/1/2023	2,796	213	-50	34	N/A
7/2/2023	2,837	250	153	227	N/A
4/2/2023	3,024	353	380	460	N/A
1/1/2023	3,312	513	594	680	N/A
10/2/2022	3,599	599	790	876	N/A
7/3/2022	3,748	637	932	1,030	N/A
4/3/2022	3,483	694	1,122	1,220	N/A
1/2/2022	3,828	889	1,325	1,411	N/A
10/3/2021	4,155	1,086	1,478	1,557	N/A
7/4/2021	4,257	1,155	1,380	1,455	N/A
4/4/2021	4,438	1,074	1,234	1,306	N/A
1/3/2021	2,663	631	829	892	N/A
10/4/2020	3,234	412	545	625	N/A
7/5/2020	2,977	294	444	521	N/A
4/5/2020	2,887	226	352	429	N/A
12/29/2019	2,884	228	282	363	N/A
9/29/2019	2,835	235	217	308	N/A
6/30/2019	2,802	251	199	294	N/A
3/31/2019	2,783	247	225	320	N/A
12/30/2018	2,778	237	218	311	N/A
9/30/2018	2,663	128	203	280	N/A
7/1/2018	2,543	149	N/A	245	N/A
4/1/2018	2,387	147	N/A	220	N/A
12/31/2017	2,257	157	N/A	288	N/A
10/1/2017	2,182	258	N/A	309	N/A
7/2/2017	2,142	215	N/A	324	N/A
4/2/2017	2,132	210	N/A	372	N/A
1/1/2017	2,116	216	N/A	351	N/A
10/2/2016	1,999	198	N/A	327	N/A
7/3/2016	2,048	199	N/A	314	N/A
4/3/2016	2,076	190	N/A	281	N/A
1/3/2016	2,105	189	N/A	287	N/A
10/4/2015	2,263	176	N/A	258	N/A
6/28/2015	2,241	164	N/A	261	N/A
3/29/2015	2,234	167	N/A	252	N/A
12/28/2014	2,070	130	N/A	282	N/A
9/28/2014	2,221	203	N/A	257	N/A
6/29/2014	2,201	201	N/A	242	N/A
3/30/2014	2,185	176	N/A	215	N/A
12/29/2013	2,158	174	N/A	159	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RVTYDas prognostizierte Gewinnwachstum (19.8% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: RVTYDie Erträge des Unternehmens (19.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: RVTYDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: RVTYDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: RVTYDie Einnahmen des Unternehmens (6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RVTYDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (7.8%).

Revvity Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Price target increased by 8.2% to US$134

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Price target increased by 8.9% to US$122

Recent updates

Scale Biosciences and Revvity's BioLegend Launch First-Of-Its-Kind Solution for High Parameter Protein Profiling of Single Cells

We Think Revvity's (NYSE:RVTY) Healthy Earnings Might Be Conservative

Dividend of US$0.07 announced

Revvity, Inc. (NYSE:RVTY) announces an Equity Buyback for $1,000 million worth of its shares.

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Third quarter 2024 earnings: EPS exceeds analyst expectations

Revvity, Inc. Declares Quarterly Dividend, Payable on February 7, 2025

Here's Why Revvity (NYSE:RVTY) Can Manage Its Debt Responsibly

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Getting In Cheap On Revvity, Inc. (NYSE:RVTY) Might Be Difficult

Second quarter 2024 earnings: EPS misses analyst expectations

Price target increased by 8.2% to US$134

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024

When Should You Buy Revvity, Inc. (NYSE:RVTY)?

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024

Revvity: Continued Struggles, 2024 Becoming A Lost Year

Is Revvity (NYSE:RVTY) Using Too Much Debt?

First quarter 2024 earnings: EPS misses analyst expectations

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity: Enter Now As Reorganization Takes Shape

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

We Think Revvity (NYSE:RVTY) Can Stay On Top Of Its Debt

Investors Can Find Comfort In Revvity's (NYSE:RVTY) Earnings Quality

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

CEO, President & Director notifies of intention to sell stock

New minor risk - Earnings quality

Price target increased by 8.9% to US$122

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings: EPS exceeds analyst expectations

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Should You Think About Buying Revvity, Inc. (NYSE:RVTY) Now?

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 49% Undervalued

Revvity: More Than A Name Change Is Needed For PerkinElmer

Why We're Not Concerned About Revvity, Inc.'s (NYSE:RVTY) Share Price

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Consensus EPS estimates fall by 15%

Price target decreased by 22% to US$107

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Earnings quality

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Is Revvity (NYSE:RVTY) Using Too Much Debt?

Revvity: Recent Investments, Acquisitions, Not Pulling Economic Weight (Rating Downgrade)

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

At US$108, Is Revvity, Inc. (NYSE:RVTY) Worth Looking At Closely?

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 40% Undervalued

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023